NCT00243074 · STUDY IN CONTEXT

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

confirmed complete and partial responses per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.".

Eligible patients who received any amount of AZD2171

→

secondary · POSTED

From the date of enrollment until the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.

Eligible patients who received AZD2171

→

secondary · POSTED

From the date of enrollment until the date of disease progression (as determined by standard RECIST), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Eligible patients who received AZD2171

→

secondary · POSTED

The percentage of patients with a best of response of stable disease or better per standard RECIST. That is, patients whose best response was not increasing disease or death.

Eligible patients who received AZD2171

→

secondary · POSTED

The sum of 6 pleural thickness measurements is added to sum of the longest diameters of all non-pleural measurable lesions. The resulting values are evaluated using RECIST.

Eligible patients who received any amount of AZD2171

→

secondary · POSTED

Adverse events per the NCI Common Toxicity Criteria version 3.0 that were possibly, probably or definitely related to protocol treatment. See adverse event tables for specific details.

All patients who received protocol treatment were assessed for adverse events. See adverse event tables for specific details.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-malignant-mesothelioma
nct id: NCT00243074
trial label: S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0000
source section id
NCT00243074-om-0000
source outcome index
0
endpoint
Overall Response Rate
endpoint definition
confirmed complete and partial responses per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.".
time origin
Disease assessments for response were performed every 8 weeks for as long as the patient remained on protocol treatment, up to 5 years.
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Eligible patients who received any amount of AZD2171
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0001
source section id
NCT00243074-om-0001
source outcome index
1
endpoint
Overall Survival
endpoint definition
From the date of enrollment until the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
time origin
Daily during protocol treatment; then every 8 weeks until progression; then every 6 months for up to 3 years.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible patients who received AZD2171
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0002
source section id
NCT00243074-om-0002
source outcome index
2
endpoint
Progression-free Survival
endpoint definition
From the date of enrollment until the date of disease progression (as determined by standard RECIST), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
time origin
Every 8 weeks until disease progression or death, up to 5 years.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible patients who received AZD2171
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0003
source section id
NCT00243074-om-0003
source outcome index
3
endpoint
Disease Control Rate
endpoint definition
The percentage of patients with a best of response of stable disease or better per standard RECIST. That is, patients whose best response was not increasing disease or death.
time origin
Every 8 weeks until disease progression progression, up to 5 years.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible patients who received AZD2171
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0004
source section id
NCT00243074-om-0004
source outcome index
4
endpoint
Objective Response Rate Per Modified RECIST for Pleural Tumors
endpoint definition
The sum of 6 pleural thickness measurements is added to sum of the longest diameters of all non-pleural measurable lesions. The resulting values are evaluated using RECIST.
time origin
Disease assessments for response were performed every 8 weeks as long as the patient remained on protocol treatment, up to 5 years.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eligible patients who received any amount of AZD2171
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0005
source section id
NCT00243074-om-0005
source outcome index
5
endpoint
Adverse Event Rates
endpoint definition
Adverse events per the NCI Common Toxicity Criteria version 3.0 that were possibly, probably or definitely related to protocol treatment. See adverse event tables for specific details.
time origin
Daily during protocol treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All patients who received protocol treatment were assessed for adverse events. See adverse event tables for specific details.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0000
arm key
OG000
arm label
AZD2171 (Cediranib Maleate)
regimen
AZD2171 (Cediranib Maleate)
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0001
arm key
OG000
arm label
AZD2171
regimen
AZD2171
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0002
arm key
OG000
arm label
AZD2171
regimen
AZD2171
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0003
arm key
OG000
arm label
AZD2171
regimen
AZD2171
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0004
arm key
OG000
arm label
AZD2171
regimen
AZD2171
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
outcome key
om-0005
arm key
OG000
arm label
AZD2171 (Cediranib Maleate)
regimen
AZD2171 (Cediranib Maleate)
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00243074-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00243074
harm key
EG000
source section id
NCT00243074-ae
event group key
EG000
event group label
AZD2171
serious affected
22
serious at risk
47
other affected
42
other at risk
47
frequency threshold
5
collection period
Daily during protocol treatment.
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice